^
    Back
    Association details:
    Biomarker:FGFR2 amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:zotatifin (eFT226) (eIF4A1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-NCI-EORTC 2019
    Title:

    B133 - eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers

    Published date:
    10/28/2019
    Excerpt:
    Solid tumor xenograft models harboring FGFR1/2 or HER2 amplifications treated with eFT226 resulted in significant in vivo tumor growth inhibition and regression at well tolerated doses in breast, non-small cell lung and colorectal cancer models.